ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >MK-4827 (tosylate)

MK-4827 (tosylate)

MK-4827 (tosylate) Suppliers list
Company Name: Kaixin Chemical (Hong Kong) Limited  Gold
Tel: 010-88886666-01 13112345678
Email: loyson@qq.com
Company Name: Changzhou Fulangke Chemical Technology Co., Ltd.  Gold
Tel: 13776872728
Email: amwpl888@sina.cn
Company Name: Chembest Research Laboratories Limited  
Tel: 021-20908456
Email: sales@BioChemBest.com
Company Name: Haoyuan Chemexpress Co., Ltd.  
Tel: 021-58950125
Email: info@chemexpress.com
Company Name: TargetMol Chemicals Inc.  
Tel: 021-021-33632979 15002134094
Email: marketing@targetmol.com

MK-4827 (tosylate) manufacturers

  • MK-4827 (tosylate)
  • MK-4827 (tosylate) pictures
  • 2026-11-12
  • CAS:1038915-73-9
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 20n tons

Related articles

  • MK-4827 (tosylate)
  • To validate that MK-4827 (Niraparib) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μM MK-4827 for....
  • Aug 26,2019
MK-4827 (tosylate) Basic information
Product Name:MK-4827 (tosylate)
Synonyms:Niraparib TsOH;niraparib p-toluenesulfonate;MK-4827(Niraparib) tosylate;MK-4827 (tosylate);(3S)-3-[4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl]piperidine tosylate;MK-4827, Niraparib TsOH salt;Niraparib(MK-4827) tosylate;NIRAPARIB TOSYLATE;MK 4827 TOSYLATE;MK4827 TOSYLATE
CAS:1038915-73-9
MF:C26H28N4O4S
MW:492.58992
EINECS:
Product Categories:
Mol File:1038915-73-9.mol
MK-4827 (tosylate) Structure
MK-4827 (tosylate) Chemical Properties
Melting point >142oC (dec.)
storage temp. -20°C Freezer
solubility Methanol (Slightly)
form Solid
color Off-White to Pale Yellow
InChIKeyLCPFHXWLJMNKNC-XOIICWPPNA-N
SMILESS(C1C=CC(C)=CC=1)(O)(=O)=O.C(C1=CC=CC2=CN(C3C=CC([C@H]4CNCCC4)=CC=3)N=C12)(=O)N |&1:23,r|
Safety Information
MSDS Information
MK-4827 (tosylate) Usage And Synthesis
DescriptionNiraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively; with significant activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP, and Tank1. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis, and shows anti-tumor activity.
UsesNiraparib is a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
in vitroIn a whole-cell assay, Niraparib (MK-4827) tosylate hydrate inhibits PARP activity with EC50=4 nM and EC90=45 nM. Niraparib tosylate hydrate inhibits the proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. Niraparib tosylate hydrate displays excellent PARP 1 and 2 inhibition with IC50=3.8 and 2.1 nM, respectively, and in a whole-cell assay. Niraparib tosylate hydrate inhibits PARP within 15 minutes of treatment, reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells.
in vivo

Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vdss=6.9 L/kg), long terminal half-life (t1/2=3.4 h), and excellent bioavailability, F=65%[1].
Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily[3].

IC 50PARP-2: 2.1 nM (IC50); PARP-1: 3.8 nM (IC50); V-PARP: 330 nM (IC50); TANK-1: 570 nM (IC50); PARP-3: 1300 nM (IC50)
References[1] PHILIP JONES*. Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors[J]. Journal of Medicinal Chemistry, 2009, 52 22: 7170-7185. DOI: 10.1021/jm901188v
[2] YUAN YUAN. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.[J]. Journal of Hematology & Oncology, 2011, 4: 16. DOI: 10.1186/1756-8722-4-16
[3] LI WANG. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.[J]. Investigational New Drugs, 2012: 2113-2120. DOI: 10.1007/s10637-011-9770-x
[4] MIRZA M, MONK B, HERRSTEDT J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.[J]. The New England Journal of Medicine, 2016, 75 1: 0. DOI: 10.1056/nejmoa1611310
MK-4827 (tosylate) Preparation Products And Raw materials
Tag:MK-4827 (tosylate)(1038915-73-9) Related Product Information
BKM120 (NVP-BKM120, Buparlisib) (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxaMide Ruxolitinib phosphate Nintedanib Triethyl orthoformate Tosyl azide EGF816 (mesylate) Epacadostat (INCB024360) Nintedanib Ethanesulfonate Salt MK-4827 (R-enantioMer) AnaMorelin hydrochloride tert-butyl (S)-3-(4-bromophenyl)piperidine-1-carboxylate Niraparib Niraparib tosylate 3-(4-Bromophenyl)piperidine-1-carboxylic acid tert-butyl ester